At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
SGMT Sagimet Biosciences Inc.
Trading 04-13 12:26:59 EDT
5.44
+0.14
+2.64%
High5.58Low5.30Vol126.80K
Open5.30D1 Closing5.30Amplitude5.28%
Mkt Cap176.92MTradable Cap123.09MTotal Shares32.52M
T/O696.99KT/O Rate0.56%Tradable Shares22.63M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Sagimet grants 9,600 inducement stock options to new hire under Nasdaq rule exception
Reuters  ·  04-06
Sagimet grants 9,600 inducement stock options to new hire under Nasdaq rule exception
Sagimet Biosciences Announces Poster and Oral Presentations at the Fueling MASH: Metabolic Drivers and Inflammatory Crosstalk Keystone Symposium and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire  ·  04-06
Sagimet Biosciences Announces Poster and Oral Presentations at the Fueling MASH: Metabolic Drivers and Inflammatory Crosstalk Keystone Symposium and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Sagimet Biosciences initiated with a Buy at Rodman & Renshaw
TIPRANKS  ·  03-26
Sagimet Biosciences initiated with a Buy at Rodman & Renshaw
Analysts Offer Insights on Healthcare Companies: Korro Bio (KRRO), Sagimet Biosciences, Inc. Class A (SGMT) and Bristol-Myers Squibb (BMY)
TIPRANKS  ·  03-13
Analysts Offer Insights on Healthcare Companies: Korro Bio (KRRO), Sagimet Biosciences, Inc. Class A (SGMT) and Bristol-Myers Squibb (BMY)
Sagimet Biosciences Inc reports results for the quarter ended December 31 - Earnings Summary
Reuters  ·  03-12
Sagimet Biosciences Inc reports results for the quarter ended December 31 - Earnings Summary
Sagimet Biosciences Price Target Maintained With a $29.00/Share by HC Wainwright & Co.
Dow Jones  ·  03-12
Sagimet Biosciences Price Target Maintained With a $29.00/Share by HC Wainwright & Co.
Sagimet: Undervalued MASH and Acne Pipeline with Best-in-Class Combination Potential Supports Buy Rating
TIPRANKS  ·  03-11
Sagimet: Undervalued MASH and Acne Pipeline with Best-in-Class Combination Potential Supports Buy Rating
Sagimet Biosciences Reports 2025 Results, Highlights Clinical Progress
TIPRANKS  ·  03-11
Sagimet Biosciences Reports 2025 Results, Highlights Clinical Progress
Sagimet Biosciences Q4 net loss narrows as R&D expenses fall
Reuters  ·  03-11
Sagimet Biosciences Q4 net loss narrows as R&D expenses fall
Sagimet Biosciences Q4 EPS $(0.29) Beats $(0.48) Estimate
Benzinga  ·  03-11
Sagimet Biosciences Q4 EPS $(0.29) Beats $(0.48) Estimate
Sagimet Biosciences Q4 net loss narrows 41% to USD 9.57 million, cash falls 29% to USD 113.12 million
Reuters  ·  03-11
Sagimet Biosciences Q4 net loss narrows 41% to USD 9.57 million, cash falls 29% to USD 113.12 million
Sagimet Biosciences Q4 EPS USD -0.29
THOMSON REUTERS  ·  03-11
Sagimet Biosciences Q4 EPS USD -0.29
Press Release: Sagimet Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates
Dow Jones  ·  03-11
Press Release: Sagimet Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates
Sagimet Biosciences Inc expected to post a loss of 41 cents a share - Earnings Preview
Reuters  ·  03-10
Sagimet Biosciences Inc expected to post a loss of 41 cents a share - Earnings Preview
Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences
GlobeNewswire  ·  02-25
Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences
Top Sagimet Executives Quietly Unload Shares in Coordinated Insider Move
TIPRANKS  ·  02-13
Top Sagimet Executives Quietly Unload Shares in Coordinated Insider Move
Sagimet Biosciences nimmt an Investorenkonferenzen von Guggenheim und Oppenheimer teil
Reuters  ·  02-05
Sagimet Biosciences nimmt an Investorenkonferenzen von Guggenheim und Oppenheimer teil
After Clearing Up Acne, Sagimet Stock Rises -- Barrons.com
Dow Jones  ·  02-04
After Clearing Up Acne, Sagimet Stock Rises -- Barrons.com
Wall Street's Top Analysts Issue Latest Ratings: Adobe Downgraded, Palantir Upgraded
Deep News  ·  02-03
Wall Street's Top Analysts Issue Latest Ratings: Adobe Downgraded, Palantir Upgraded
Sagimet Biosciences Price Target Maintained With a $29.00/Share by HC Wainwright & Co.
Dow Jones  ·  02-03
Sagimet Biosciences Price Target Maintained With a $29.00/Share by HC Wainwright & Co.

Introduction

Company Name.
Sagimet Biosciences Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Issue price:
--